Biotech Licensing Often More Cost-Effective Than In-House R&D For Pharma
Executive Summary
Large pharmaceutical manufacturers are entering into more early stage licensing deals with biotechs because such deals are often more cost-effective than conducting in-house research, Bayer VP-Business Development Chris Seaton said
You may also be interested in...
GSK Says No To Early Stage Deal-Making, Citing High Likelihood Of Failure
GlaxoSmithKline's in-licensing efforts will focus on late-stage compounds due to the high risk of earlier stage deals, CEO J.P. Garnier said Feb. 8
Licensing An Adjunct To In-House R&D, Not A Substitute – AstraZeneca Exec
AstraZeneca views licensing and acquisitions as an add-on to, rather than a replacement for, internal research & development, Exec Director-Development John Patterson said Sept. 19
Licensing An Adjunct To In-House R&D, Not A Substitute – AstraZeneca Exec
AstraZeneca views licensing and acquisitions as an add-on to, rather than a replacement for, internal research & development, Exec Director-Development John Patterson said Sept. 19